Blaha L, Burkard G, Lehrl S, Kapinas K
Arzneimittelforschung. 1979;29(8a):1295-301.
A double-blind study was carried out on 56 geronto-psychiatric in-patients who suffered from cerebral metabolic and nutritional disturbances to prove the effectiveness of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate (nicergoline, Sermion). After a washout-phase of eight days the patients in the verum group received 3 x 1 dragée at 10 mg for a period of 12 weeks. For methodical reasons only patients with slight transit syndromes and, of these, only the first four weeks of examination were included in the present analysis. Thus 8 verum and 9 placebo patients remain whose findings during the trial are recorded in three procedures of capacity and two procedures of self-assessment (syndrome short test, repeating figures and letters, reading letters; scale for general somatic discomfort, scale for vegetative functional disturbances). In the measuring procedures there is a tendency towards improvement under the treatment with nicergline compared with placebo during the first three weeks. But the present results are not sufficient to come to a clear decision on the effectiveness of nicergoline in patients with cerebrovascular insufficiency.
对56名患有脑代谢和营养紊乱的老年精神病住院患者进行了一项双盲研究，以证明10-甲氧基-1,6-二甲基麦角灵-8β-甲醇-（5-溴烟酸酯）（尼麦角林，喜得镇）的有效性。在为期8天的洗脱期后，试验组患者接受3次10毫克的糖衣丸，为期12周。出于方法学原因，本分析仅纳入了患有轻度过渡综合征的患者，并且仅包括这些患者检查的前四周。因此，有8名试验组患者和9名安慰剂组患者，其试验期间的结果记录在三项能力测试程序和两项自我评估程序（综合征简短测试、重复数字和字母、阅读字母；一般躯体不适量表、植物神经功能紊乱量表）中。在前三周的测量程序中，与安慰剂相比，尼麦角林治疗下有改善的趋势。但目前的结果不足以就尼麦角林对脑血管供血不足患者的有效性做出明确判断。
